The pediatric preclinical testing program: Description of models and early testing results

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|49|7|928-940

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.49, Iss.7, 2007-12, pp. : 928-940

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of CPX‐351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 1, 2015-01 ,pp. : 65-71

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1106-1109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 1545-5009, Iss. 11, 2015-11 ,pp. : 1897-1905

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 11, 2015-11 ,pp. : 1897-1905

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 2, 2014-02 ,pp. : 245-252

John Wiley & Sons Inc

Access to resources Recommend Favorite